Skip to content

Compare

Saxenda vs Xenical

Quick read · 5 min

Last reviewed: September 2026Based on 2 clinical trialsEvery claim linked to source

Saxenda (liraglutide, daily injection) and Xenical (orlistat, capsule, three times daily with meals) are both approved for weight loss in the United States. No head-to-head trial has compared these two drugs. The figures below come from separate trials, each with its own participants, length and comparison group.

At a glance

Saxenda and Xenical compared on form, trial results, cost and reported side effects
 SaxendaXenical
FormDaily injection3x daily with meals
How oftenDaily injectionThree capsules daily, taken with each fat-containing meal
Weight loss in trialsUp to 8% — SCALE Obesity and Prediabetes (56 weeks)Up to 8.5% — Sjostrom 1-year RCT (52 weeks)
FDA approved20141999
Made byNovo NordiskRoche (Xenical) / GSK (Alli OTC)
How it worksA GLP-1 analogue with a half-life of approximately 13 hours (requiring daily injection).Blocks pancreatic lipase enzymes in the small intestine, preventing approximately 30% of dietary fat from being broken down and absorbed.
Monthly cost, self-pay$1,000–$1,349/mo$40–$400/moover-the-counter strength; prescription runs to $400
Most reported reactionNausea 40% (SCALE Obesity and Prediabetes)Oily/fatty stools (steatorrhoea) 27% (XENDOS)

Every figure in this table is read from the same trial and label records used everywhere else on this site.

Weight loss in each drug's main trial

No head-to-head trial has compared these two drugs.

Saxenda(liraglutide)8%

SCALE Obesity and Prediabetes (56 weeks)

Xenical(orlistat)8.5%

Sjostrom 1-year RCT (52 weeks)

In clinical trials, participants taking liraglutide lost on average up to 8% of their starting body weight, and participants taking orlistat lost on average up to 8.5%. Those numbers come from two different studies: SCALE Obesity and Prediabetes enrolled 3,731 adults with obesity or overweight with comorbidities over 56 weeks against placebo, while Sjostrom 1-year RCT enrolled 743 adults with obesity over 1 year (52 weeks) against placebo. Who took part, how long each trial ran and what each drug was measured against all move the percentage, so the two figures are not a measured difference between the drugs.

Monthly cost, self-pay

The bar spans the range in each drug's price record — lowest listed price to highest.

Saxenda$1,000–$1,349/mo

Brand (Saxenda) ~$1,000–$1,349/month. Generic liraglutide is typically $135–$200 less than brand.

Xenical$40–$400/mo

over-the-counter strength; prescription runs to $400

Prescription Xenical ~$200–$400/month; over-the-counter Alli (60mg) ~$40–$60/month.

Self-pay prices are what the manufacturer or the pharmacy lists, not what most people end up paying. Saxenda: $1,000–$1,349/month. Xenical: $40–$400/month. Insurance, dose and pharmacy all change both figures.

Side effects reported in the trials

SCALE Obesity and Prediabetes and XENDOS did not report the same reactions, so there is no shared row to line up. Each drug's own reported rates are listed below.

Saxenda
  • Nausea40%
  • Diarrhoea21%
  • Constipation19%
  • Vomiting16%

From SCALE Obesity and Prediabetes

Xenical
  • Oily/fatty stools (steatorrhoea)27%
  • Faecal urgency22%
  • Oily spotting on underwear27%
  • Faecal incontinence8%
  • Abdominal pain/discomfort14%

From XENDOS

A rate is the share of trial participants who reported that reaction, not a prediction for any one person.

How they differ in practice

How you take it

  • SaxendaOnce-daily subcutaneous injection
  • XenicalOral capsule 120 mg, three times daily with meals (prescription). Also available OTC as Alli at 60 mg.

Dose build-up

  • Saxenda0.6 mg → 3.0 mg, escalated over 4 weeks

Where a drug is not listed here, its prescribing information sets out its own dose steps.

How soon it acts

  • SaxendaEffects visible within 4–8 weeks; maximum benefit typically by 56 weeks
  • XenicalWeight effects begin from the first week (related to calorie malabsorption), but significant loss takes 8–12 weeks

Heart and metabolic findings

  • SaxendaThe LEADER trial (type 2 diabetes) showed cardiovascular benefit.
  • XenicalIn the 4-year XENDOS trial, orlistat reduced progression from prediabetes to type 2 diabetes by 37% compared to placebo plus lifestyle changes.

As stated in each drug’s trial record — not a claim about which drug protects the heart more.

Other findings recorded

  • SaxendaApproved for adolescents aged 12 and over (SCALE teens programme); generic liraglutide now available (Teva, August 2025) — reducing out-of-pocket cost
  • Xenical37% reduction in progression to type 2 diabetes (XENDOS, 4 years); only approved obesity drug with a 4-year safety dataset

If you stop taking it

  • SaxendaWeight regain after stopping is expected, as with other GLP-1 drugs.
  • XenicalWeight is typically regained after stopping.

Common questions

Written and maintained by one person · Built with agentic AI tools · Every number checked against the cited trial · Not medical advice

How this site is built →

Next step most people take

Built with agentic AI tools and not a substitute for medical advice

Last reviewed:

Medical disclaimer: This website is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment.